Medical device acquirers spent something in the neighborhood of $1.5 billion over the past few months on transcatheter mitral valve replacement acquisitions to treat just 80 patients, half of whom are now dead, Boston Scientific (NYSE:BSX) chief medical officer Dr. Keith Dawkins said today.
“There’s been, really [since] a few months ago, $1.5 billion, roughly, spent on about 80 patients, 40 of whom are dead,” Dawkins said at the annual J.P. Morgan healthcare conference in San Francisco.
